Background: Hepatitis C virus recurrence after liver transplantation is universal, leading to chronic hepatitis and cirrhosis. Aims and patients: We evaluated the efficacy and safety of pegylated interferon and ribavirin in 20 patients with recurrent Hepatitis C virus after liver transplantation (10 naïve and 10 non-responders to a previous interferon course). Methods: Treatment consisted of pegylated interferon alfa-2b (1.0 μg/kg once weekly) and ribavirin (600 mg/daily) for at least 6 months. Therapy continued for an additional 6 months only in patients with undetectable serum Hepatitis C virus-RNA or >2 log drop from baseline levels. Results: Eleven out of 20 patients (55%) completed 1 year of treatment. Nine patients (45%) had undetectable Hepatitis C virus-RNA at the end of treatment, six of them were naïves and three non-responders. In all of them, virological response persisted 6 months after discontinuation of therapy, so the sustained virological response rate was 60% in naïve patients and 30% in non-responders. Conclusions: Our results suggest that pegylated interferon plus ribavirin combination therapy may be effective in patients with post-liver transplantation recurrent chronic Hepatitis C, even in those previously non-responders to interferon plus ribavirin. These results need to be confirmed by large studies

Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppressive regimen / Biselli M; Andreone P; Gramenzi A; Lorenzini S; Loggi E; Bonvicini F; Cursaro C; Bernardi M.. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - STAMPA. - 38:(2006), pp. 27-32. [10.1016/j.dld.2005.08.009]

Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppressive regimen.

BISELLI, MAURIZIO;ANDREONE, PIETRO;GRAMENZI, ANNAGIULIA;LOGGI, ELISABETTA;BONVICINI, FIORENZA;BERNARDI, MAURO
2006

Abstract

Background: Hepatitis C virus recurrence after liver transplantation is universal, leading to chronic hepatitis and cirrhosis. Aims and patients: We evaluated the efficacy and safety of pegylated interferon and ribavirin in 20 patients with recurrent Hepatitis C virus after liver transplantation (10 naïve and 10 non-responders to a previous interferon course). Methods: Treatment consisted of pegylated interferon alfa-2b (1.0 μg/kg once weekly) and ribavirin (600 mg/daily) for at least 6 months. Therapy continued for an additional 6 months only in patients with undetectable serum Hepatitis C virus-RNA or >2 log drop from baseline levels. Results: Eleven out of 20 patients (55%) completed 1 year of treatment. Nine patients (45%) had undetectable Hepatitis C virus-RNA at the end of treatment, six of them were naïves and three non-responders. In all of them, virological response persisted 6 months after discontinuation of therapy, so the sustained virological response rate was 60% in naïve patients and 30% in non-responders. Conclusions: Our results suggest that pegylated interferon plus ribavirin combination therapy may be effective in patients with post-liver transplantation recurrent chronic Hepatitis C, even in those previously non-responders to interferon plus ribavirin. These results need to be confirmed by large studies
2006
Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppressive regimen / Biselli M; Andreone P; Gramenzi A; Lorenzini S; Loggi E; Bonvicini F; Cursaro C; Bernardi M.. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - STAMPA. - 38:(2006), pp. 27-32. [10.1016/j.dld.2005.08.009]
Biselli M; Andreone P; Gramenzi A; Lorenzini S; Loggi E; Bonvicini F; Cursaro C; Bernardi M.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/23047
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 43
  • ???jsp.display-item.citation.isi??? 30
social impact